NEW YORK (Reuters Health), Jun 30 - Late prostate cancer morbidity and biochemical failure rates appear similar with hypofractionated or conventional 3D radiation therapy (RT), according to a report from Italy.
There's an emerging trend toward using hypofractionated regimens for clinically localized disease, and this study provides clinical evidence to support it, said researcher Dr. Giovanni Luca Gravina, of the University of L'Aquila, and colleagues.
In a May 26 online paper in BJU International, they reviewed the outcomes of 162 men with prostate cancer. Eighty-two received 3D hypofractionated RT (15 fractions of 3.62 Gy delivered three times/wk; total dose 54.3 Gy), and 80 received 3D conventional RT (39 fractions of 2 Gy delivered daily; total dose 78 Gy).
Both groups received a short course of hormone therapy concomitantly with the radiation therapy.
The average compliance rates were 89% and 93% in the hypofractionated and conventional groups, respectively.
Overall, one patient (2%) in the conventional group and two (4%) in the hypofractionated group had late grade 3 genitourinary toxicity (three years after RT). Three men (5%) in the conventional group and two (4%) in the hypofractionated group had late grade 3 gastrointestinal toxicity.
No one in either group had late grade 4 toxicities.
At a median follow-up of 45 months for the hypofractionated group and 58 months for the conventional group, disease progression rates were 22% (18/82) and 25% (20/80), respectively.
There was no significant worsening in the risk of biochemical failure.
"Further studies and longer follow-up will be required to confirm the present results," the researchers say.
http://www3.interscience.wiley.com/journal/123476591/abstract
BJU Int 2010.
Last Updated: 2010-06-29 17:39:50 -0400 (Reuters Health)
Related Reading
Prior radiation increases complications after prostatectomy, June 24, 2010
Radiotherapy for prostate cancer may delay diagnosis of bladder cancer, April 5, 2010
Tumor tracking for prostate IMRT reduces GI side effects, March 26, 2010
Higher RT dose improves outcomes for prostate cancer patients, December 14, 2009
Few major complications in 30 days after prostate radiotherapy, February 13, 2009
Copyright © 2010 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
